
OR WAIT null SECS
For World COPD Day, Vickram Tejwani, MD, says single exacerbations warrant urgency and calls out gaps in spirometry use and initial COPD therapy.
Clinicians should treat even a single chronic obstructive pulmonary disease (COPD) exacerbation as a serious event warranting a treatment review rather than an expected part of the disease, according to Vickram Tejwani, MD, assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine and pulmonologist in the Cleveland Clinic Respiratory Institute. Tejwani discussed gaps in COPD diagnosis, initial therapy, and exacerbation prevention in an interview with HCPLive for World COPD Day.
World COPD Day, held annually by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), falls on November 18, 2026. GOLD's 2027 report, set for release the same day, recommends a long-acting muscarinic antagonist (LAMA) as initial therapy for group A patients.1 Tejwani said stigma tied to tobacco smoke has limited attention to COPD in the US, although much of the global burden stems from biomass exposure such as wood stove cooking.
He said many patients remain undiagnosed because diagnosis depends on effort-dependent, high-quality spirometry. He recommended spirometry for anyone with dyspnea, cough, or sputum production without an obvious nonpulmonary explanation, noting the test involves no blood draw or radiation.
Tejwani coauthored a claims analysis of patients in the Optum Clinformatics Data Mart database newly starting inhaled maintenance therapy, in which 48.3% began a long-acting β-agonist (LABA)/inhaled corticosteroid (ICS) combination.2 He said initial treatment should instead be LABA and/or LAMA bronchodilation, with ICS added for patients with high eosinophil counts or continued exacerbations, followed by specialist referral for advanced therapies.
"The number of patients I have where they tell me that their COPD is well controlled, and then when I ask them, say, 'Oh yeah, I just take a couple of bursts of prednisone a year,' and that's kind of perceived as well controlled," Tejwani said.
Tejwani said mortality after a COPD hospitalization is comparable to mortality after a hospitalization for myocardial infarction. He added that terms like "exacerbation" or "flare" fail to convey the same urgency, which has prompted talk in the field of calling them "lung attacks." He said exacerbations harm lung function, quality of life, and survival, can aggravate comorbid cardiovascular disease, and even short prednisone bursts carry significant long-term consequences.
Historically, patients were counseled to expect flares despite optimal inhaled therapy, Tejwani said. Azithromycin, roflumilast, and newer anti-inflammatory therapies, including biologics, have since expanded options to reduce exacerbation risk.
Tejwani had no relevant disclosures.
References